Document:

<PAGE>

                                LICENSE AGREEMENT

         This License Agreement ("Agreement") is made as of December 15, 1999
(the "Effective Date") by and between the California Institute of Technology, a
California Corporation, having a place of business at 1201 E. California
Boulevard, Pasadena, California 91125 ("Caltech") and Digital Personnel, Inc.
(DPI), a Florida Corporation, having a place of business at 202 South Wheeler
Street, Plant City, Florida 33566.

                                    RECITALS

         A. Caltech owns certain Patent Rights, Software, Technology and Know
How (as defined below), and

         B. DPI has an option to license from Caltech the Patent Rights,
Software, Technology and Know How, and DPI now wishes to obtain a license to
them on the terms and conditions set forth below.

         NOW, THEREFORE, in consideration of the mutual covenants and promises
herein contained, the parties hereto agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS
                                   -----------

         As used in this Agreement, the following terms shall have the meanings
indicated:

         1.1 "Affiliate" shall mean any entity which controls, is controlled by
or is under common control with DPI. An entity shall be regarded as in control
of another entity for purposes of this definition if it owns or controls more
than fifty percent (50%) of the shares of the subject entity entitled to vote in
the election of directors (or, in the case of an entity that is not a
corporation, more than fifty percent (50%) control in the election or
appointment of the corresponding managing authority)

<PAGE>

         1.2 "Fee for Service" shall mean revenues received by DPI and/or
Affiliates for services performed in connection with the sale of Licensed
Product.

         1.3 "Know How" shall mean any and all knowledge possessed or owned by
Cal Tech that would assist DPI in utilizing and exploiting the Patent Rights,
Software and Technology.

         1.4 "Licensed Product" shall mean a product, composition or material
the manufacture, offer for sale, sale or use of which would, but for the license
granted herein, infringe a Valid Claim in the country for which such product,
composition or material is manufactured, offered for sale, sold or used.

         1.5 "Licensed Subject Matter" means (a) worldwide rights to the
inventions described and claimed in the patents, patent applications and
invention disclosures listed in Exhibit A attached hereto; any patents which
issue on the applications or disclosures listed in Exhibit A; reissues,
reexaminations, renewals, extensions, divisionals, continuations, and
continuations-in-part of the foregoing; and any foreign counterparts and any
other forms of protection directed to the inventions covered by the patents,
applications and invention disclosures listed in Exhibit A, and (b) all patent
applications hereafter filed and owned by Caltech or jointly with DPI, which are
dominated by a claim or claims of the patents or patent applications of part
(a).

         1.6 "Licensed Software" shall mean any computer program utilized in
practicing the invention(s) giving rise to the Patent Rights.

         1.7 "Net Sales" shall mean Fee for Service plus revenues received by
DPI and/or Affiliates from Sublicensees due to license fees or as the result of
a sale of Licensed Product by Sublicensees, plus the total revenue generated
from the sale of Licensed Products to third parties by DPI and/or its
Affiliates, for which royalties are due under Article 5 below, less the
following reasonable and customary deductions to the extent applicable to such
total revenue:

                                       2

<PAGE>

(i) all trade, cash and quantity credits, discounts, refunds or government
rebates; (ii) amounts for claims, allowances or credits for returns, retroactive
price reductions, or charge backs; (iii) packaging, handling fees and prepaid
freight, sales taxes, duties and other governmental charges (including value
added tax); and (iv) provisions for uncollectible accounts determined in
accordance with reasonable accounting practices, consistently applied to all
products of the selling party.

         1.8 "Patent Rights" shall mean any and all rights in and to any
Technology and Know How embodied in:

             (a) The patent applications listed in Exhibit A hereto; any patents
         issuing on such patent applications, any foreign counterparts of such
         patent applications and patents, and any patent or application anywhere
         in the world to the extent (and only to the extent) such patent or
         application discloses subject matter disclosed, and makes claims made,
         in any of the patent applications in Exhibit A or the foreign
         counterparts thereof (collectively, "Existing Patents");

             (b) All divisions, continuations, Continuations-in-Part, patents of
         Addition, substitutions, registrations, reissues, reexaminations or
         extensions of any kind with respect to any of the Existing Patents.

             (c) "Continuation-in-Part" shall include patent applications and/or
         patent claiming priority from a filing date of any Existing Patent (i)
         only to the extent new matter is directed to subject matter described
         in such Existing Patent and originating from, at a minimum, at least
         one of the inventor(s) named in such Existing Patent, and DPI.
         exclusive .doc shall exclude new matter not described in such Existing
         Patent, and (ii) only if at least one (1) of the inventors named in the
         Existing Patent from which priority is claimed is named as an inventor
         for such patent application or patent. "Patents of Addition" shall
         include non-United States patent applications and patents (a) only to
         the extent new matter is directed to subject matter described in any
         Existing Patent and originating from, at a minimum, at least one of the
         inventor(s) named in such Existing Patent and shall exclude new matter
         not described in such Existing Patent, and (b) only if at least one (1)
         of the inventors named in the Existing patent to which the patent of
         addition relates is a named as an inventor for such patent application
         or patent.

                                        3
<PAGE>

         1.9 "Sublicensee" shall mean any non-Affiliate third party to whom DPI
has granted the right to manufacture, sell, offer for sale and/or use Licensed
Products. It is understood and agreed that the foregoing definition of
Sublicensee shall not limit the scope of sublicenses that DPI may grant
hereunder.

          1.10 "Technology" shall mean software listed in Exhibit A, and all
proprietary information, know-how, procedures, methods, prototypes, designs,
technical data and reports owned by Caltech offered by Caltech and accepted by
DPI, in each case, necessary or useful in the development of Licensed Products
and which relate to the Licensed Products, but which are not the subject of the
Licensed Patent Rights. Subject to the foregoing, inventions which are the
subject of applications for patents listed in Exhibit A or applications which
claim priority thereon or are Improvements and which do not issue into patents
shall be considered to be Technology.

         1.11 "Valid Claim" shall mean a claim of an issued and unexpired patent
or a claim of a pending patent application within the Patent Rights which has
not been held unpatentable, invalid or unenforceable by a court or other
government agency of competent jurisdiction and has not been admitted to be
invalid or unenforceable through reissue, re-examination, disclaimer or
otherwise; provided, however, that if the holding of such court or agency is
later reversed by a court or agency with overriding authority, the claim shall
be reinstated as a Valid Claim with respect to Net Sales made after the date of
such reversal. Notwithstanding the foregoing provisions of this Section 1.9, if
a claim of a pending patent application within the Patent Rights has not issued
as a claim of an issued patent within the patent Rights, within five (5) years
after the filing date from which such claim takes priority, such pending claim
shall not be a Valid Claim for purposes of this Agreement.

          1.12 "Revenues" shall mean payments received by DPI its Affiliates
from the sale of Licensed Products by DPI or its Sublicensees which shall
include, but not be limited to, payments for technical assistance, know-how and
Technology.

                                        4

<PAGE>

                                    ARTICLE 2

                         REPRESENTATIONS AND WARRANTIES
                         ------------------------------

         2.1 Caltech. Caltech represents and warrants to DPI that (i) Caltech is
and shall be the owner of the entire right, title, and interest in and to
Licensed Subject Matter; (ii) Caltech has not previously granted and will not
grant any rights in the Licensed Subject Matter that are inconsistent with the
rights and licenses granted to DPI herein; (iii) there are no claims of any
third parties that would call into question the rights of Caltech to grant to
DPI the rights and licenses contemplated hereunder; (iv) to the best of its
knowledge as of the Effective Date practice of the inventions/technology coming
within the ambit of the Patent Rights will not infringe any intellectual
property rights of third parties; and (v) except for the Patent Rights, and the
inventions disclosed therein, including but not limited to the Technology and
Know How, as of the Effective Date, Caltech does not own or control rights: 1)
to any patent, patent application or invention pertaining to phoneme-based
artificial image reconstruction of speech, the claims of which would dominate
and/or prevent the practice of any technology/invention coming within the ambit
of the Patent Rights; or 2) to any source code copyright that would prevent DPI
from utilizing the Licensed Software.

         2.2 Disclaimer. EXCEPT AS PROVIDED IN THIS ARTICLE 2, NEITHER PARTY
MAKES ANY WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE)
WITH RESPECT TO THE SUBJECT MATTER HEREOF, AND CALTECH SPECIFICALLY DISCLAIMS
ANY AND ALL IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE.

                                    ARTICLE 3

                                     LICENSE
                                     -------
         3.1 Grants.

             (a) Caltech hereby grants to DPI and Affiliates a worldwide,
         royalty-free exclusive (except as otherwise expressly provided in
         Section 3.3 below) license under the Licensed Subject Matter to: (i)
         make, have made, use, Sell, offer for sale, import, export or otherwise
         distribute Licensed Products, (ii) practice any method, process or
         procedure under, and otherwise exploit, the Licensed Subject Matter;
         and (iii) to have any of the foregoing performed on DPI's behalf by a
         third party. At its option, DPI shall have the right to convert this
         license to a non-exclusive license. In all cases, all rights to any
         improvements upon the Licensed Subject Matter made by DPI and/or an
         Affiliate shall be owned solely and exclusively by DPI and/or such
         Affiliate.

                                        5
<PAGE>

             (b) Caltech hereby grants to DPI and Affiliates a worldwide,
         royalty-free, exclusive (except as otherwise expressly provided in
         Sections 3.3 and 3.4 below) license to use and copy the Licensed
         Software, and any improvements and/or derivative works thereof solely
         as a result of work conducted at JPL under DPI's sponsorship, or made
         jointly with DPI or any Affiliate. All rights to any improvements
         and/or derivative works developed by DPI and/or any Affiliate, or on
         behalf of DPI and/or such Affiliate, shall be owned solely and
         exclusively by DPI and/or such Affiliate.

         3.2 Sublicenses. DPI may grant and authorize sublicenses within the
scope of the licenses granted to DPI pursuant to this Agreement.

         3.3 Recognizing that Caltech's exclusive licenses to DPI are to the
exclusion of Caltech itself, DPI agrees to grant to Caltech a non-exclusive,
non-transferable, royalty-free license back to any inventions, software,
information or data that Caltech has licensed to DPI, but only for the purposes
of research internal to Caltech, as well as any purpose for or on behalf of the
United States Government.

                                    ARTICLE 4

                                COMPUTER SOFTWARE
                                -----------------

         4.1 Delivery. Upon execution of this Agreement, to the extent that the
Licensed Software has not already been delivered to DPI, Caltech shall deliver
to DPI the Licensed Software and all documentation associated therewith. Within
30 days of creation, if created under DPI-sponsored research pursuant to
Paragraph 5.1, Caltech shall deliver to DPI any derivative work based on, or
other improvement to, the Licensed Software, which shall then become part of the
Licensed Software.

                                        6
<PAGE>

                                    ARTICLE 5

                              PAYMENTS AND REPORTS
                              --------------------

         5.1 Equity. In consideration for the rights and licenses granted by
Caltech to DPI hereunder, DPI shall issue to Caltech Two Million, Nine Hundred
Thousand (2,900,000) shares of DPI Common Stock (29% of the Authorized shares of
DPI). This is in addition to the One Hundred Thousand (100,000) shares of DPI
Common Stock (1% of the Authorized shares of DPI) already paid to Caltech for
the Exclusive Option Agreement pertaining to this technology, dated March 1998,
and reproduced in Exhibit B.

         5.2 Equity in DPI will vest as follows:

             5.2.1   1,000,000 shares upon execution of this Agreement

             5.2.2   1,000,000 shares upon completion of the 1st R&D milestone

             5.2.3    900,000 shares upon completion of the 2nd R&D milestone

             R&D milestones are defined in the sponsored Research Contract
contained in Exhibit C.

         5.3 Patent Expenses. DPI shall reimburse Caltech a sum of Four Thousand
Dollars (US$4,000) for out-of-pocket expenses of filing, prosecuting and
maintaining the patents and patent applications in the Patent Rights prior to
the Effective Date and from the Effective Date through the Commencement Date of
this Agreement. This amount shall be paid with 30 days of the execution of this
Agreement. Caltech and DPI will work together to formulate and execute an
appropriate patent strategy. DPI will bear all reasonable, on-going patent costs
associated with filing and maintaining patent applications and patents related
to Licensed Technology as described in Section 11.1 of this Agreement.

                                        7
<PAGE>

         5.4 Sponsored Research. DPI shall fund a 12-24 month sponsored research
program at the Jet Propulsion Laboratory (JPL) to further develop this
technology. The total amount of the funding to be provided will be no less than
Four Hundred Thousand Dollars ($400,000), or, if agreed between the parties a
lesser amount will be provided to JPL in order to expedite the development and
commercialization of Licensed Products externally. The funding of this program
will begin within 12 months of the Effective Date of this License Agreement. If
DPI does not provided this sponsored research funding within 12 months of the
effective date of this Agreement than this License Agreement will be terminated
and all Licensed Rights will revert back to Caltech.

         5.5 Records; Inspection. DPI shall keep complete, true and accurate
books of account. Such books and records shall be kept reasonably accessible for
at least three (3) years following the end of the calendar quarter to which they
pertain. Such records will be open for inspection during such three- (3) year
period by a representative or agent of Caltech for the purpose of understanding
business progress. Such inspections may be made no more than once each calendar
year, at reasonable times mutually agreed by DPI and Caltech. Caltech's
representative or agent will be obliged to execute a reasonable confidentiality
agreement prior to commencing any such inspection. Caltech shall bear the costs
and expenses of inspections conducted under this Section 5.5.

                                    ARTICLE 6

                                  DUE DILIGENCE
                                  -------------

         6.1 DPI shall have discretion over the commercialization of the
Licensed Subject Matter. However, DPI agrees to use its best efforts to
introduce commercially one or more Licensed Product(s) in the United States as
soon as practical, consistent with sound and reasonable business practices and
judgments. DPI shall be deemed to have satisfied its obligations under this
Paragraph 6.1 if DPI has an ongoing and active research program or marketing
program, as appropriate, directed toward bringing such Licensed Products to
market and meeting the market demand herefore. Any efforts of DPI sublicensees
shall be considered efforts of DPI for the sole purpose of determining DPI's
compliance with its obligation under this paragraph.

                                        8
<PAGE>

         6.2 After the first year from the Effective Date, Caltech shall have
the right, no more often than once per year upon sixty (60) days written notice
to DPI, to require DPI to report to Caltech in writing on its efforts in
complying with Section 6.1 above.

         6.3 If DPI is not fulfilling its obligations under Paragraph 6.1 and
Caltech so notifies DPI in writing, Caltech and DPI shall negotiate in good
faith any additional efforts to be taken by DPI. If the parties do not reach
agreement within ninety (90) days, any additional efforts shall be determined in
accordance with Article 12. If DPI fails to make any required efforts, after
they are so determined, and does not remedy that failure within sixty (60) days
after further written notice to DPI, Caltech may convert the relevant license to
a nonexclusive license.

                                    ARTICLE 7

                              TERM AND TERMINATION
                              --------------------

         7.1 Term. Unless terminated earlier pursuant to this Article 7, the
term of this Agreement shall commence on the Effective Date and continue in full
force and effect until expiration, revocation or invalidation of the last patent
or the abandonment of the last patent application within the Patent Rights,
whichever is later. DPI's license with respect to the Technology and Know How
shall survive the expiration, (but not an earlier termination, except as
provided in Section 7.5 below) of this Agreement.

                                        9
<PAGE>

         7.2 Caltech shall have the right to terminate this Agreement if DPI
fails to make any payment due hereunder and DPI continues to fail to make the
payment, either to Caltech directly or by placing any disputed amount into an
interest bearing escrow account to be released when the dispute is resolved, for
a period of sixty (60) days after receiving notice from Caltech specifying DPI's
failure. Upon any such termination Caltech shall accept an assignment by DPI of
any sublicenses granted by DPI to entities other than Related Companies, and any
sublicense so assigned shall remain in full force and effect.

         7.3 Termination for Breach. In the event of a material breach of this
Agreement, the non-breaching party shall be, entitled to terminate this
Agreement by written notice to the breaching party, if such breach is not cured
within ninety (90) days after written notice is given by the non-breaching party
to the breaching party specifying the breach. However, if the party alleged to
be in breach of this Agreement disputes such breach within such ninety (90) day
period, the non-breaching party shall not have the right to terminate this
Agreement unless it has been determined by a court of competent jurisdiction
that this Agreement was materially breached, and the breaching party fails to
comply with its obligations hereunder within ninety (90) days after such
determination.

         7.4 Termination Upon Notice. Any provision herein notwithstanding, DPI
may terminate this Agreement, in its entirely or as to any particular patent or
patent application within the Patent Rights, or as to any particular Licensed
Product, at any time by giving Caltech at least thirty (30) days prior written
notice. From and after the effective date of such termination under this Section
7.4 with respect to a particular patent or patent application, such patent(s)
and application(s) in the particular country shall cease to be within the Patent
Rights for all purposes of this Agreement, and all rights and obligations of DPI
with respect to such patent(s) and patent application(s) shall terminate; from
and after the effective date of a termination under this Section 7.4 with
respect to particular Licensed Product, the license granted to DPI under Section
3.1 shall terminate with respect to such Licensed Product. Upon termination of
this Agreement in its entirety under this Section 7.4, all rights and
obligations of the parties shall terminate, except as provided in Section 7.5
below.

                                       10
<PAGE>

         7.5 Survival.

         7.5.1 Termination of this Agreement for any reason shall not release
either party hereto from any liability, which at the time of such termination
has already accrued to the other party.

         7.5.2 In the event this Agreement is terminated for any reason, DPI and
its Affiliates shall have the right to sell or otherwise dispose of the stock of
any Licensed Products then on hand, all subject to the payment to Caltech of
fees and royalties pursuant to Article S hereof. Upon termination of this
Agreement by Caltech for any reason, any sublicense granted by DPI hereunder
shall survive, provided that upon request by Caltech, such Sublicensee promptly
agrees in writing to be bound by the applicable terms of this Agreement.

         7.5.3 Articles 1, 2, 7, 9, 10, 12 and 13 and Sections 5.13 and 11.1
shall survive the expiration and any termination of this Agreement. Except as
otherwise provided in this Article 7, all rights and obligations of the parties
under this Agreement shall terminate upon the expiration or termination of this
Agreement.

                                    ARTICLE 8

                           INFRINGEMENT BY THIRD PARTY
                           ---------------------------

         8.1 Enforcement. During the term of this Agreement, in the event that
either party hereto reasonably believes that any Licensed Subject Matter and/or
Licensed Software is being infringed or otherwise misappropriated by a third
party or in the event that a declaratory judgement action is brought against
such party with respect to the Licensed Subject Matter and/or Licensed Software,
such party shall promptly notify the other party.

         8.2 Actions. As between the parties to this Agreement, DPI (itself or
through others) shall, at its expense, have the initial right to control the
enforcement of the Licensed Subject Matter and/or Licensed Software or defend
any declaratory judgment action with respect thereto (each for the purposes of
this Article 8, an "Enforcement Action").

         8.3 Caltech. In the event that DPI does not initiate an Enforcement
Action to enforce the Licensed Subject Matter and/or Licensed Software against
commercially significant infringement or misappropriation by a third party in a
country, within one hundred eighty (180) days of a request by Caltech to
initiate such Enforcement Action or thereafter diligently pursue such
Enforcement Action, Caltech or its designee may initiate an Enforcement Action
against such infringement or misappropriation at its own expense.
Notwithstanding the foregoing, DPI shall have the exclusive right to sublicense
any alleged infringer pursuant to Section 3.1 above.

                                       11
<PAGE>

         8.4 Cooperation. The non-controlling party shall, at the controlling
Party's reasonable request and expense, fully cooperate with the party
controlling any Enforcement Action; including but not limited to, joining as a
party-plaintiff, using best efforts to cause its employees to testify at such an
action and to make available relevant records, papers, information, samples,
specimens and the like. The party controlling the Enforcement Action shall keep
the non-controlling party reasonably informed of the progress of such action,
and the non-controlling shall have the right to participate in such Enforcement
Action with counsel of its own choice at its own expense.

         8.5 Division of Recoveries. All recoveries from an Enforcement Action
shall be first applied to reimburse the controlling party's, and then the
non-controlling party's, unreimbursed expenses, including without limitation,
reasonable attorneys' fees and court costs. Any remainder shall be divided
between the parties as follows:

         8.5.1 To the extent the amount recovered reflects lost profits, DPI
               shall retain the remainder; or

         8.5.1 To the extent the amount recovered does not reflect lost profits,
               seventy-five percent (75%) shall be paid to DPI and, twenty-five
               percent (25%) to Caltech.

                                    ARTICLE 9

                                 INDEMNIFICATION
                                 ---------------

         9.1 Indemnification of Caltech. DPI shall hold Caltech, its directors,
trustees, officers, employees, agents and the successors and assigns of any of
the foregoing (collectively, the "Indemnitees") harmless against any and all
claims brought by third parties alleging personal injury or property damage in
conjunction with, or arising out of (1) practice by DPI, its Affiliates and
Sublicensees, their directors, trustees, officers, employees, contractors,
subcontractors and agents, of the Patent Rights or (2) the design, manufacture,
distribution or use of Licensed Products; provided that any Indemnitee seeking
indemnification hereunder shall (i) promptly notify DPI of such claim (ii) give
sole control of the defense or settlement of such claim, and (iii) provide DPI,
at DPI's expense, with reasonable assistance and full information with respect
to such claim. Notwithstanding the foregoing, DPI shall have no obligations for
any claim if the Indemnitee seeking indemnification makes any admission,
settlement or other communication regarding such claim without the prior written
consent of DPI, which consent shall not be unreasonably withheld. Such indemnity
shall include all costs and expenses, including reasonable attorneys' fees and
any costs of settlement.

                                   ARTICLE 10

                                  USE OF NAMES
                                  ------------

         10.1 Party Names. Except as required by law or in the normal course of
business identification and description, neither DPI nor Caltech shall issue any
press release or other public statements in connection with this Agreement
intended for use in the public media in a manner suggesting any endorsement by
the other of DPI or Caltech, respectively, without the approval of such other
party, which approval shall not be unreasonably withheld.

                                       12
<PAGE>

                                   ARTICLE 11

                          INVENTIONS/PATENT PROSECUTION
                          -----------------------------

         11.1 Prosecution by DPI. Subject to Section 11.2 below, DPI shall have
the right, at its option, to control the filing for, prosecution and maintenance
of the Patent Rights; provided however that DPI shall furnish to Caltech copies
of documents relevant to any such filing, prosecution and maintenance. For
purposes of this Article 11, "prosecution and maintenance" of patents and patent
applications shall be deemed to include, without limitation, the conduct of
interferences or oppositions, and/or requests for re-examinations, reissues or
extensions of patent terms. DPI shall reimburse Caltech for all reasonable
out-of-pocket expenses incurred by Caltech after the Commencement Date for the
filing for, prosecution and maintenance of the Patent Rights. Such payments
shall be due thirty (30) days following receipt of invoice by DPI for such
expenses. If DPI elects to no longer pay the expenses of a patent or patent
application within the Patent Rights in any country, DPI shall notify Caltech
not less than thirty (30) days prior to such action and the license granted to
DPI hereunder with respect to such patent or patent application shall become
nonexclusive.

         11.2 Prosecution by Caltech. If DPI elects not to file, prosecute or
maintain any patent application or patent within the Patent Rights or pay any
fee related thereto, in any country DPI shall promptly notify Caltech of such
election, but in no case later than sixty (60) days prior to any required action
relating to the filing, prosecution or maintenance of such patent application or
patent. In such event, and if Caltech elects to take over the filing,
prosecution and/or maintenance of one or more patents or applications within the
Patent Rights, then in any such case, upon notice to DPI, Caltech shall have the
right, at its option, to control the filing, prosecution and/or maintenance of
any such patent applications or patents within the Patent Rights at its own
expense. In the event that Caltech takes over the filing, prosecution and/or
maintenance of a patent or application within the Patent Rights, Caltech shall
keep DPI reasonably informed on matters regarding such filing, prosecution and
maintenance.

                                   ARTICLE 12

                                     GENERAL
                                     -------

         12.1 Governing Law. This Agreement shall be governed by, and construed
and interpreted in accordance with, the laws of California, without regard to
conflicts of laws principles.

                                       14
<PAGE>

         12.2 Independent Contractors. The relationship of DPI and Caltech
established by this Agreement is that of independent contractors. Nothing in
this Agreement shall be construed to create any other relationship between DPI
and Caltech. Neither party shall have any right, power or authority to assume,
create or incur any expense, liability or obligation, express or implied, on
behalf of the other.

         12.3 Assignment. This Agreement may not be assigned by DPI without the
prior written consent of Caltech, not to be unreasonably withheld, except to a
party that succeeds to all or substantially all of DPI's business or assets
relating to this Agreement whether by sale, merger, operation of law or
otherwise; provided that such assignee or transferee agrees in writing to be
bound by the terms and conditions of this Agreement. Caltech may assign its
right to receive payments hereunder upon prior written notice to DPI but may not
otherwise transfer or assign this agreement without the prior written consent of
DPI, not to be unreasonably withheld.

         12.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE
OTHER PARTY OR ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR
INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING
TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH
CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN
AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR
LIKELIHOOD OF SAME.

         12.5 No Implied Obligations. DPI's sole obligation to exploit the
Licensed Subject Matter is as set forth in Article 6. Nothing in this Agreement
shall be deemed to require DPI to otherwise exploit the Licensed Subject Matter
nor prevent DPI from commercializing products similar to or competitive with a
Licensed Product.

         12.6 Force Majeure. In the event either party hereto is prevented from
or delayed in the performance of any of its obligations hereunder by reason of
acts of God, war, strikes, riots, storms, fires, or any other cause whatsoever
beyond the reasonable control of the party, the party so prevented or delayed
shall be excused from the performance of any such obligation to the extent and
during the period of such prevention or delay

                                       15
<PAGE>

         12.7 Notices. Any notice or other communication required by this
Agreement shall be made in writing and given by prepaid, first class, certified
mail, return receipt requested, and shall be deemed to have been served on the
date received by the addressee at the following address or such other address as
may from time to time be designated to the other party in writing:

          If to Caltech:                 California Institute of Technology
                                         1200 E. California Blvd. (M/C 210-85)
                                         Pasadena, California 91125
                                         Attn: Larry Gilbert
                                         Director- Office of Technology transfer

          If to DPI:                     Digital Personnel Inc.
                                         202 South Wheeler Street
                                         Plant City, Florida 33566
                                         Attn: Clifford M. Gross, Ph.D.
                                         President

         12.8 Compliance with Law. DPI shall comply with all applicable federal,
state and local laws and regulations in connection with its activities pursuant
to this Agreement.

         12.9 Modification Waiver. This Agreement may not be altered, amended or
modified in any way except by a document signed by both parties. The failure of
a party to enforce any provision of this Agreement shall not be construed to be
a waiver of the right of such party to thereafter enforce that provision or any
other provision or right.

         12.10 Headings. Headings included herein are for convenience only, do
not form a part of this Agreement and shall not be used in any way to construe
or interpret this Agreement.

         12.11 Severability. If any provision of this Agreement shall be found
by a court to be void, invalid or unenforceable, the same shall be reformed to
comply with applicable law or stricken if not so conformable, so as not to
affect the validity or enforceability of the remainder of this Agreement.

         12.12 Entire Agreement. The parties hereto acknowledge that this
Agreement and its Exhibits set forth the entire agreement and understanding of
the parties hereto as to the subject matter hereof, and supersedes all prior
discussions, agreements and writings in respect hereto.

                                       16
<PAGE>

         12.13 Counterparts. This Agreement may be executed in counterparts,
each of which shall be deemed an original, but both or which together shall
constitute one and the same instrument.

                                   ARTICLE 13

                                PRODUCT LIABILITY
                                -----------------

         13.1 DPI agrees that Caltech shall have no liability to DPI or to any
purchasers or users of Licensed Products made or sold by/for its Sublicensees
for any claims, demands, losses, costs, or damages suffered by DPI or purchasers
or users of Licensed Products, or any other party, which may result from
personal injury, death, or property damage related to the manufacture, use or
sale of such Licensed Products ("Claims"). DPI agrees to defend, indemnify and
hold harmless Caltech, its trustees, officers, agents, and employees from any
such Claims, provided that (i) DPI is notified promptly of any Claims, (ii) DPI
has the sole right to control and defend or settle any litigation within the
scope of this indemnity, and (iii) all indemnified parties cooperate to the
extent necessary in the defense of any Claims, all as set forth in Section 9.1
above.

         13.2 At such time as DPI begins to sell or distribute or sublicense
Licensed Products (other than for the purpose of obtaining regulatory
approvals), based upon use of Licensed Subject Matter, DPI shall at its sole
expense, procure and maintain policies of comprehensive general liability
insurance in amounts not less than $2,000,000 per incident and $2,000,000 in
annual aggregate and naming those indemnified under Section 13.1. as additional
insureds. Such comprehensive general liability insurance shall provide (i)
product liability coverage and (ii) broad form contractual liability coverage
for DPI's indemnification under Section 13.1. In the event the aforesaid product
liability coverage does not provide for occurrence liability, DPI shall maintain
such comprehensive general liability insurance for a reasonable period of not
more than seven (7) years after it has ceased commercial distribution or use of
any Licensed Product. Notwithstanding the foregoing, a plan of self-insurance
reasonably expected to provide coverage comparable to the foregoing for recovery
of anticipated claims shall satisfy DPI's obligation under this Section 13.2.

                                       17

<PAGE>

         13.3 DPI shall provide Caltech with written evidence of such insurance
upon request of Caltech. DPI shall provide Caltech with notice at least fifteen
(15) days prior to any cancellation, non-renewal or material change in such
insurance, to the extent DPI receives advance notice of such matters from its
insurer. If DPI does not obtain replacement insurance providing comparable
coverage within sixty (60) days following the date of such cancellation,
non-renewal or materials change, Caltech shall have the right to require that
DPI cease further commercial sales of Licensed Products until such insurance is
obtained for such Licensed Products; provided that if DPI uses reasonable
efforts but is unable to obtain the required insurance at commercially
reasonable rates, Caltech shall not have the right to so require such cessation
of sales, and Caltech instead shall cooperate with DPI to either grant a waiver
of DPI under this Article 13 or assist DPI in identifying a carrier to provide
such insurance or in developing a program for self-insurance or other
alternative measures. This Article 13 shall survive the expiration or
termination of this Agreement.

         IN WITNESS WHEREOF, the parties hereto have caused their duly
authorized representatives to execute this Agreement.

CALIFORNIA INSTITUTE OF                          Digital Personnel, Inc. ("DPI")
TECHNOLOGY ("Caltech")

By:                                              By:
Lawrence Gilbert                                        Clifford M. Gross, Ph.D.
Director                                                President
Office of Technology Transfer

Date: _________________                          Date:

                                       18<PAGE>

                                LICENSE AGREEMENT

Effective as of March 28, 2000 ("Effective Date") The Johns Hopkins University,
a corporation of the State of Maryland, having a principal place of business at
3400 North Charles Street, Baltimore, MD 21218 (hereinafter referred to as
"JHU") and Zorax, Inc., a Florida Corporation and a wholly owned subsidiary of
UTEK Corporation, a Delaware Corporation, having a principal place of business
at 202 South Wheeler Street, Plant City, Florida 33566(hereinafter the
"Company") agree as follows:

                            ARTICLE 1 -- BACKGROUND

1.1      JHU has an assignment of "Apparatus for the Separation of Cystic
         Parasite Forms From Water", inventors C.J. Shiff and T.K.Graczyk
         ("Invention[s]"), as described in JHU Docket 1304, US Serial
         # 09/006,999, filed 1 /14/98, and any Licensed Patent(s), as
         hereinafter defined, which may issue to such Invention(s).

1.2      JHU has certain technical data and information as herein defined
         ("Technology") pertaining to Invention(s).

1.3      JHU has acquired through assignment all rights, title and interest,
         with the exception of certain retained rights by the United States
         government, in said valuable invention; and

1.4      JHU, as a center for research and education, JHU desires to have the
         Technology and Invention(s) perfected and marketed at the earliest
         possible time in order that products resulting therefrom may be
         available for public use and benefit.

1.5      JHU is interested in licensing PATENT RIGHTS (hereinafter defined) in a
         manner that will benefit the public by facilitating the distribution of
         useful products and the utilization of new methods, but is without
         capacity to commercially develop, manufacture, and distribute any such
         products or methods.

1.6      Company desires a license under said Technology, Invention(s) and
         Licensed Patent(s) to develop, manufacture, use and distribute such
         products and processes throughout the world in all fields of use.

NOW, THEREFORE, in consideration of the foregoing premises and the following
mutual covenants, and other good and valuable consideration, the receipt of
which is hereby acknowledged, and intending to be legally bound hereby, the
parties agree as follows:

                             ARTICLE 2 - DEFINITIONS

2.1      "PATENT RIGHTS" shall mean the U.S. Patent Application Serial No.
         09/006,999, entitled"Apparatus for the Separation of Cystic Parasite
         Forms From Water", inventors C.J. Shiff and T.K.Graczyk and assigned to
         JHU (hereinafter the "PATENT APPLICATION") and the invention disclosed
         and claimed therein, and all continuations, divisions, and reissues
         based thereof, and any corresponding foreign patent applications, and
         any patents, patents of addition, or other equivalent foreign patent
         rights issuing, granted or registered thereon.

2.2      "TECHNOLOGY" means existing technical data and information, including,
         but not limited to, the

<PAGE>

         information contained in the Patent Application pertaining to the
         Invention(s) and provided to the Company whether or not it is of a
         confidential nature.

2.3      "LICENSED PRODUCT(S)" means any product or part thereof in the Licensed
         Field of Use, the manufacture, use or sale of which:

         a.       would constitute, but for the license granted to the Company
                  pursuant to this Agreement, an infringement of a claim of
                  PATENT RIGHTS (infringement shall include, but is not limited
                  to, direct, contributory, or inducement to infringe).

         b.       incorporates any of the Technology.

2.4      "NET SALES", subject to Paragraph 6.5, below, shall mean gross revenues
         and fees billed by Company, AFFILIATED COMPANY and Company's
         sublicensees from the sale of LICENSED PRODUCT(S), whether or not
         assembled (and without excluding therefrom any components or
         subassemblies thereof, whatever their origin and whether or not it
         falls within the scope of a claim), less the following items but only
         insofar as they actually pertain to the disposition of such Licensed
         Product(s) by Company, AFFILIATED COMPANY or Company's sublicensee(s),
         are included in such gross revenue, and are separately billed:

         a.       Import, export, excise and sales taxes, and custom duties;

         b.       Costs of insurance, packaging, and transportation from the
                  place of manufacture to the customer's premises or point of
                  installation;

         c.       Costs of installation at the place of use; and

         d.       Credit for returns, allowances, or trade discounts.

In the event that Company, AFFILIATED COMPANY or Company's sublicensee sells a
LICENSED PRODUCTS) in combination with other ingredients or substances, the NET
SALES for purposes of royalty payments shall be based on the sales revenues and
fees received from the entire combination.

2.5      "AFFILIATED COMPANY" or "AFFILIATED COMPANIES" shall mean any
         corporation, company, partnership, joint venture or other entity which
         controls, is controlled by or is under common control with the Company.
         For purposes of this Paragraph 2.5, control shall mean the direct or
         indirect ownership of at least fifty percent (50%).

2.6      "EXCLUSIVE LICENSE" shall mean a grant by JHU to Company of its entire
         right and interest in the PATENT RIGHTS, subject to rights retained by
         the United States government in accordance with P.L. 96-517, as amended
         by P.L. 98-620, and subject to the retained right of JHU to make, have
         made, provide and use for its' non-profit purposes LICENSED PRODUCT(S).

                               ARTICLE 3 - GRANTS

3.1      Subject to the terms and conditions of this Agreement, JHU hereby
         grants and Company hereby accepts, an EXCLUSIVE LICENSE, with the right
         to sublicense others pursurant to Article 9, to make, have made, use,
         sell, and import the LICENSED PRODUCTS) in the United States and
         worldwide underthe PATENT RIGHTS.

<PAGE>

3.2      Company may sublicense others under this Agreement, subject to Article
         9, and shall provide a copy of each such sublicense agreement to JHU
         promptly after it is executed. Each sublicense shall be consistent with
         the terms of this Agreement.

3.3      JHU shall have the right to practice the Invention(s) and use the
         Technology for its own bona fide research, including sponsored research
         and collaborations. JHU shall have the right to publish any information
         included in Technology and Licensed Patent(s).

                          ARTICLE 4 - GOVERNMENT RIGHTS

This Agreement is subject to all of the terms and conditions of Title 35 United
States Code Sections 200-204, including an obligation that Licensed Product(s)
sold or produced in the United States be "manufactured substantially in the
United States," and Company agrees to take all reasonable action necessary on
its part as licensee to enable JHU to satisfy its obligation thereunder,
relating to Invention(s).

                         ARTICLE 5 - PATENT INFRINGEMENT

5.1      Each party will notify the other promptly in writing when any
         infringement by another is uncovered or suspected.

5.2      Company shall have the first right to enforce any patentwithin PATENT
         RIGHTS against any infringement or alleged infringement thereof, and
         shall at all times keep JHU informed as to the status thereof. Company
         may, in its sole judgment and at its own expense, institute suit
         against any such infringer or alleged infringer and control, settle,
         and defend such suit in a manner consistent with the terms and
         provisions hereof and recover, for its account, any damages, awards or
         settlements resulting therefrom, subject to Paragraph 5.4. This right
         to sue for infringement shall not be used in an arbitrary or capricious
         manner. JHU shall reasonably cooperate in any such litigation at
         Company's expense.

5.3      If Company elects not to enforce any patent within the PATENT RIGHTS,
         then it shall so notify JHU in writing within six (6) months of
         receiving notice that an infringement exists, and JHU may, in its sole
         judgment and at its own expense, take steps to enforce any patent and
         control, settle, and defend such suit in a manner consistent with the
         terms and provisions hereof, and recover, for its own account, any
         damages, awards or settlements resulting therefrom.

5.4      Any recovery by Company under Paragraph 5.2 shall be deemed to reflect
         loss of commercial sales, and Company shall pay to JHU fifteen percent
         (15%) of the recovery net of all reasonable costs and expenses
         associated with each suit or settlement. If the cost and expenses
         exceed the recovery, then one-half (1/2) of the excess shall be
         credited against royalties payable by Company to JHU hereunder in
         connection with sales in the country of such legal proceedings,
         provided, however, that any such credit under this Paragraph 5.4 shall
         not exceed fifty percent (50%) of the royalties otherwise payable to
         JHU with regard to sales in the country of such action in any one
         calendar year, with any excess credit being carried forward to future
         calendar years.

                     ARTICLE 6 - PAYMENTS, ROYALTY, REPORTS

6.1      Company shall reimburse JHU for the reasonable costs of preparing,
         filing, maintaining and prosecuting PATENT RIGHTS incurred after the
         Effective Date of this Agreement. Company shall

<PAGE>

         reimburse JHU within thirty (30) days of receipt of invoice from JHU.

6.2      Company shall pay JHU fifteen thousand dollars ($15,000) within 30 days
         of the Effective Date of this Agreement as the up-front fee for the
         exclusive license to this TECHNOLOGY.

6.3      Company shall pay to JHU earned royalties of two and one half percent
         (2.5%) of NET SALES for the term of this Agreement. Such payments shall
         be made quarterly as provided in Paragraph 6.6.

6.4      Company shall pay the following minimum royalties beginning 24 months
         after the Effective Date:

         6.4.1    3rd anniversary:          $3,000
         6.4.2    4th anniversary:          $3,500
         6.4.3    5th anniversary:          $4,000
         6.4.4    6th anniversary:          $4,500
         6.4.5    7th anniversary and each anniversary thereafter until the end
                  of patent life: $5,000.

6.5      Company shall provide Zorax, Inc common stock equal to 9% of currently
         outstanding shares (as of the Effective Date).

6.5.1    In the event that Zorax is sold. TM will agree to sell their shares to
         the acquirer and in consideration JHU will receive 9% of the total
         consideration issued for all of Zorax's shares.

6.6      The Company shall provide to JHU within thirty (30) days of the end of
         each March; June, September and December after the EFFECTIVE DATE of
         this Agreement, a written report to JHU of the amount of LICENSED
         PRODUCTS sold, the total NET SALES of such LICENSED PRODUCTS and the
         earned royalties due to JHU as a result of NET SALES by Company,
         AFFILIATED COMPANIES and sublicensees thereof. Payment of any such
         royalties due shall accompany such report.

Until the Company, an AFFILIATED COMPANY or a sublicensee has achieved a first
commercial sale of a LICENSED PRODUCT, a report shall be submitted at the end of
every June and December after the EFFECTIVE DATE of this Agreement. Such report
shall include, as a minimum, information sufficient to enable JHU to satisfy
reporting requirements of the US Government and for JHU to ascertain progress by
Company's, AFFILIATED COMPANIES or sublicensee's technical efforts towards
meeting the diligence requirements in Article 8.

6.7      Company shall make and retain, for a period of three (3) years
         following the period of each report required by Paragraph 6.4 true and
         accurate records, files and books of account containing all the data
         reasonably required for the full computation and verification of sales
         and other information required in Paragraph 6.4. Such books and records
         shall be in accordance with generally accepted accounting principles
         consistently applied. The Company shall permit the inspection and
         copying of such records, files and books of account by JHU or its
         agents during regular business hours upon two (2) business days'
         written notice to the Company. Such inspection shall not be made more
         than once each calendar year. All costs of such inspection and copying
         shall be paid by JHU, provided that if any such inspection shall reveal
         that an error has been made in the amount equal to five percent (5%) or
         more of such payment, such costs shall be borne by the Company. The
         Company shall include in any agreement with its AFFILIATED COMPANIES or
         its sublicensees which permits such party to make, use or sell the
         LICENSED PRODUCTS) or provide LICENSED SERVICES, a provision requiring
         such party to retain records of sales of LICENSED PRODUCTS)

<PAGE>

         and records of LICENSED SERVICES and other information as required in
         Paragraph 6.4 and permit JHU to inspect such records as required by
         this Paragraph 6.5.

6.8      In order to insure JHU the full royalty payments contemplated
         hereunder, the Company agrees that in the event any LICENSED PRODUCT
         shall be sold to an AFFILIATED COMPANY or sublicensee or to a
         corporation, firm or association with which Company shall have any
         agreement, understanding or arrangement with respect to consideration
         (such as, among other things, an option to purchase stock or actual
         stock ownership, or an arrangement involving division of profits or
         special rebates or allowances) the royalties to be paid hereunder for
         such LICENSED PRODUCTS shall be based upon the greater of: 1) the net
         selling price at which the purchaser of LICENSED PRODUCTS resells such
         product to the end user, 2) the net service revenue received from using
         the LICENSED PRODUCT in providing a service, 3) the fair market value
         of the LICENSED PRODUCT or 4) the net selling price of LICENSED
         PRODUCTS paid by the purchaser.

6.9      All payments under this Agreement shall be made in U.S. Dollars.

             ARTICLE 7 - PATENT RIGHTS AND CONFIDENTIAL INFORMATION

7.1      JHU, at the Company's expense, shall file, prosecute and maintain all
         patents and patent applications specified under PATENT RIGHTS upon
         authorization of the Company and the Company shall be licensed
         thereunder. Title to all such patents and patent applications shall
         reside in JHU. JHU shall have full and complete control over all patent
         matters in connection therewith under the PATENT RIGHTS. The Company
         will provide payment authorization to JHU at least one (1) month before
         an action is due, provided that the Company has received timely notice
         of such action from JHU. Failure to provide authorization can be
         considered by JHU as a Company decision not to authorize an action. In
         any country where the Company elects not to have a patent application
         filed or to pay expenses associated with filing, prosecuting, or
         maintaining a patent application or patent, JHU may file, prosecute,
         and/or maintain a patent application or patent at its own expense and
         for its own exclusive benefit and the Company thereafter shall not be
         licensed under such patent or patent application.

7.2      Company agrees that all packaging containing individual LICENSED
         PRODUCT(S) sold by Company, AFFILIATED COMPANIES and sublicensees of
         Company will be marked with the number of the applicable patent(s)
         licensed hereunder in accordance with each country's patent laws.

7.3      If necessary, the parties will exchange information which they consider
         to be confidential. The recipient of such information agrees to accept
         the disclosure of said information which is marked as confidential at
         the time it is sent to the recipient, and to employ all reasonable
         efforts to maintain the information secret and confidential, such
         efforts to be no less than the degree of care employed by the recipient
         to preserve and safeguard its own confidential information. The
         information shall not be disclosed or revealed to anyone except
         employees of the recipient who have a need to know the information and
         who have entered into a secrecy agreement with the recipient under
         which such employees are required to maintain confidential the
         proprietary information of the recipient and such employees shall be
         advised by the recipient of the confidential nature of the information
         and that the information shall be treated accordingly. The recipient's
         obligations under this Paragraph 7.3 shall not extend to any part of
         the information:

         a.       that can be demonstrated to have been in the public domain or
                  publicly known and readily available to the trade or the
                  public prior to the date of the disclosure; or

<PAGE>

         b.       that can be demonstrated, from written records to have been in
                  the recipient's possession or readily available to the
                  recipient from another source not under obligation of secrecy
                  to the disclosing party prior to the disclosure; or

         c.       that becomes part of the public domain or publicly known by
                  publication or otherwise, not due to any unauthorized act by
                  the recipient; or

         d.       that is demonstrated from written records to have been
                  developed by or for the receiving party without reference to
                  confidential information disclosed by the disclosing party.

The obligations of this Paragraph 7.3 shall also apply to AFFILIATED COMPANIES
and/or sublicensees provided such information by Company. JHU's, the Company's,
AFFILIATED COMPANIES, and sublicensees' obligations under this Paragraph 7.3
shall extend until three (3) years after the termination of this Agreement.

             ARTICLE 8 - TERM DILIGENCE. MILESTONES AND TERMINATION

8.1      This Agreement shall expire in each country on the date of expiration
         of the last to expire patent included within PATENT RIGHTS in that
         country or if no patents issue seventeen (17) years from the Effective
         Date of this Agreement.

8.2      Zorax has the right to terminate this Agreement with 60 days written
         notice to JHU, providing all monies owed to JHU as of the date of
         notice of Termination have been fully paid to JHU. In the event of
         Termination, all rights to JHU TECHNOLOGY will revert back to JHU.

8.3      As an inducement to JHU to enter into this Agreement, Company agrees to
         use best efforts to proceed with the development, manufacture, and sale
         or lease of Licensed Product(s) and to diligently develop markets for
         the LICENSED PRODUCT(S). To this end, Company shall meet the following
         milestones:

         (A)      Company shall invest at least $30,000 in developing the
                  Technology within the first 12 months after the Execution
                  Date.

         (B)      Company shall supply JHU with a business development plan
                  reasonably acceptable to JHU with concrete product development
                  and marketing milestones delineated within 60 days of the
                  first anniversary of this Agreement. Should company fail to
                  provide such a plan or meet the milestones in the plan, JHU
                  shall have the right to immediately terminate this Agreement.

8.4      After first commercial sale, Company shall exercise its best efforts to
         market a product included in LICENSED PRODUCTS in the U.S. and
         worldwide.

8.5      After evidence, provided in writing by JHU or by another party, to
         Company, demonstrates the practicality of a particular application of
         the Technology which is not being developed or commercialized by
         Company, Company shall either provide JHU with a reasonable development
         plan and start development or attempt to reasonably sublicense the
         particular technology to a third party. If within six (6) months of
         such notification by JHU, Company has not initiated such development
         efforts or sublicensed that particular application of the Technology,
         JHU may terminate this license for such particular application. This
         Paragraph 8.4 shall not be applicable if Company

<PAGE>

         reasonably demonstrates to JHU that commercializing such LICENSED
         PRODUCTS) or granting such a sublicense would have a potentially
         adverse commercial effect upon marketing or sales of the LICENSED
         PRODUCTS developed and being sold by Company.

8.6      Upon breach or default of any of the terms and conditions of this
         Agreement, the defaulting party shall be given written notice of such
         default in writing and a period of sixty (60) days after receipt of
         such notice to correct the default or breach. If the default or breach
         is not corrected within said sixty (60) day period, the party not in
         default shall have the right to terminate this Agreement. Failure to
         meet any of the milestones in paragraph 8.2 shall be considered a
         breach.

8.7      Termination shall not affect JHU's right to recover unpaid royalties or
         fees or reimbursement for patent expenses incurred pursuant to
         Paragraph 7.1 prior to termination. Upon termination all rights in and
         to the licensed technology shall revert to JHU at no cost to JHU.

                       ARTICLE 9 - NEGATION OF WARRANTIES

JHU does not warrant the validity of any patents or that practice under such
patents shall be free of infringement of patents, copyrights, and other rights
of third parties. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 9, COMPANY,
AFFILIATED COMPANIES AND SUBLICENSEES AGREE THAT THE PATENT RIGHTS ARE PROVIDED
"AS IS", AND THAT JHU MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE
PERFORMANCE OF LICENSED PRODUCTS) AND LICENSED SERVICES INCLUDING THEIR SAFETY,
EFFECTIVENESS, OR COMMERCIAL VIABILITY.

JHU DISCLAIMS ALL WARRANTIES WITH REGARD TO PRODUCTS) AND SERVICES LICENSED
UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESS OR
IMPLIED, OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE.

NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, JHU ADDITIONALLY
DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF JHU AND INVENTORS, FOR
DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL, AND
CONSEQUENTIAL DAMAGES, ATTORNEYS' AND EXPERTS' FEES, AND COURT COSTS (EVEN IF
JHU HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING
OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE PRODUCTS) AND
SERVICES LICENSED UNDER THIS AGREEMENT. COMPANY, AFFILIATED COMPANIES AND
SUBLICENSEES ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED
BY A PRODUCT AND SERVICE MANUFACTURED, USED, OR SOLD BY COMPANY, ITS
SUBLICENSEES AND AFFILIATED COMPANIES WHICH IS A LICENSED PRODUCT OR LICENSED
SERVICE AS DEFINED IN THIS AGREEMENT.

Nothing in this Agreement shall be construed as:

2.       an obligation to bring or prosecute actions or suits against third
parties for infringement, except to the extent and in the circumstances
described in Article 12.

3.       Granting, by implication or estoppel, or otherwise any licenses or
rights under patents or other rights of JHU or other persons other than
Licensed Patent(s), regardless of whether such patents or

<PAGE>

         other rights are dominant or subordinate to any Licensed Patent(s); or

4.       An obligation to furnish any technology or technological information
other than the Technology.

                             ARTICLE 9 -- SUBLICENSE

9.1      Company may sublicense others under this Agreement and shall provide a
         copy of each such sublicense agreement to JHU promptly after it is
         executed. Each sublicense shall be consistent with the terms of this
         Agreement.

9.2      If Company is unable or unwilling to serve or develop a potential
         market or market territory for which there is a willing sublicensee(s),
         Company will, at JHU's request, negotiate in good faith a sublicense(s)
         hereunder.

9.3      Any sublicense(s) granted by LICENSEE under this Agreement shall be
         subject and subordinate to terms and conditions of this Agreement,
         except:

         a.       Sublicense terms and conditions shall reflect that any
                  sublicensee(s) shall not further sublicense;

         and

         b.       The earned royalty rate specified in the sublicense(s) may be
                  at higher rates than the rates in this Agreement.

Any such sublicense(s) also shall expressly include the provisions of Articles
17.2. 7.3. 8.4. 8.7 and 9) forthe benefit of JHU and provide for the transfer of
all obligations, including the payment of royalties specified in such
sublicense(s), to JHU or its designee, in the event that this Agreement is
terminated.

9.4      Company must provide JHU with 1.25% royalty on Net Sales of all
         products sold by its sublicensee(s) which incorporate LICENSED
         TECHNOLOGY

                            ARTICLE 10 -MISCELLANEOUS

10.1     All notices pertaining to this Agreement shall be in writing and sent
         certified mail, return receipt requested, to the parties at the
         following addresses or such other address as such party shall have
         furnished in writing to the other party in accordance with this
         Paragraph 10.1:

FOR JHU:  Nina M. Siegler, C.F.A.
          Director, Office of Technology Transfer
          Johns Hopkins University
          708 N. Wyman Park Center
          3400 N. Charles Street
          Baltimore, MD 21218
               Phone: (410) 516-8137
               FAX: (410) 516-7811
               E-mail: nms@jhu.edu

<PAGE>

FOR Company: Uwe Reischl, M.D., Ph.D.
             President
             Zorax, Inc.
             202 South Wheeler Street
             Plant City, FI 3566
                  Phone: (813) 654-6113
                  FAX: (813) 754-2383
                  E-mail: ureischl@utekcorp.com

10.2     All written progress reports, royalty and other payments, and any other
         related correspondence shall be in writing and sent to:

FOR JHU: Nina M. Siegler, C.F.A.
         Director, Office of Technology Transfer
         Johns Hopkins University
         708 N. Wyman Park Center
         3400 N. Charles Street
         Baltimore, MD 21218
              Phone: (410) 516-8137
              FAX: (410) 516-7811
              E-mail: nms@jhu.edu

or such other addressee which JHU may designate in writing from time to time.
Checks are to be made payable to "Johns Hopkins University".

10.3     This Agreement is binding upon and shall inure to the benefit of JHU,
         its successors and assignees and shall not be assignable to another
         party without the written consent of JHU, which consent shall not be
         unreasonably withheld, except that the Company shall have the right to
         assign this Agreement to another party without the consent of JHU in
         the case of the sale or transfer by the Company of all, or
         substantially all, of its assets relating to the LICENSED PRODUCT or
         LICENSED SERVICE, to that party.

10.4     In the event that any one or more of the provisions of this Agreement
         should for any reason be held by any court or authority having
         jurisdiction over this Agreement, or over any of the parties hereto to
         be invalid, illegal or unenforceable, such provision or provisions
         shall be reformed to approximate as nearly as possible the intent of
         the parties, and if unreformable, shall be divisible and deleted in
         such jurisdictions; elsewhere, this Agreement shall not be affected.

10.5     The construction, performance, and execution of this Agreement shall be
         governed by the laws of the State of Maryland.

10.6     The Company shall not use the name of THE JOHNS HOPKINS UNIVERSITY or
         THE JOHNS HOPKINS HEALTH SYSTEM or THE JOHNS HOPKINS SCHOOL OF HYGIENE
         AND PUBLIC HEALTH or any of its constituent parts or any contraction
         thereof or the name of inventors of PATENT RIGHTS in any advertising,
         promotional, sales literature or fundraising documents without prior
         written consent from JHU. Company shall allow at least seven (7)
         business days notice of any proposed public disclosure for JHU's review
         and comment or to provide written consent.

10.7     JHU warrants that it has good and marketable title to its interest in
         the inventions claimed under

<PAGE>

         PATENT RIGHTS with the exception of certain retained rights of the
         United States government.

10.8     JHU and the inventors of LICENSED PRODUCTS) will not, under the
         provisions of this Agreement or otherwise, have control over the manner
         in which Company or its AFFILIATED COMPANIES or its sublicensees or
         those operating for its account or third parties who purchase LICENSED
         PRODUCTS) from any of the foregoing entities, practice the inventions
         of LICENSED PRODUCT(S). Company shall defend and hold JHU, and its
         constituent parts, their present and former regents, trustees,
         officers, inventors of PATENT RIGHTS, agents, faculty, employees and
         students harmless as against any judgments, fees, expenses, or other
         costs arising from or incidental to any product liability or other
         lawsuit, claim, demand or other action brought as a consequence of the
         practice of said inventions by any of the foregoing entities, whether
         or not JHU or said inventors, either jointly or severally, is named as
         a party defendant in any such lawsuit. Practice of the inventions
         covered by LICENSED PRODUCTS) by an AFFILIATED COMPANY or an agent or a
         sublicensee or a third party on behalf of or for the account of Company
         or by a third party who purchases LICENSED PRODUCTS) from the Company,
         shall be considered Company's practice of said inventions for purposes
         of this Paragraph 10.8. The obligation of Company to defend and
         indemnify as set out in this Paragraph 10.8 shall survive the
         termination of this Agreement.

10.9     Prior to first commercial sale of any LICENSED PRODUCT as the case may
         be in any particular country, Company shall establish and maintain, in
         each country in which Company, an AFFILIATED COMPANY or sublicensee
         shall test or sell LICENSED PRODUCT(S), product liability or other
         appropriate insurance coverage appropriate to the risks involved in
         marketing LICENSED PRODUCTS) and will annually present evidence to JHU
         that such coverage is being maintained. Upon JHU's request, Company
         will furnish JHU with a Certificate of Insurance of each product
         liability insurance policy obtained and agrees to increase or change
         the kind of insurance pertaining to the LICENSED PRODUCTS) at the
         request of JHU. JHU shall be listed as an additional insured in
         Company's said insurance policies.

10.10    JHU may publish manuscripts, abstracts or the like describing the
         PATENT RIGHTS and inventions contained therein provided confidential
         information of Company as defined in Paragraph 7.3, is not included or
         without first obtaining approval from the Company to include such
         confidential information. Otherwise, JHU and the inventors shall be
         free to publish manuscripts and abstracts or the like directed to the
         work done at JHU related to the licensed technology without prior
         approval.

10.11    This Agreement constitutes the entire understanding between the parties
         with respect to the obligations of the parties with respect to the
         subject matter hereof, and supersedes and replaces all prior
         agreements, understandings, writings, and discussions between the
         parties relating to said subject matter.

10.12    This Agreement maybe amended and any of its terms or conditions maybe
         waived only by a written instrument executed by the authorized
         officials of the parties or, in the case of a waiver, by the party
         waiving compliance. The failure of either party at anytime or times to
         require performance of any provision hereof shall in no manner affect
         its right at a later time to enforce the same. No waiver by either
         party of any condition or term in any one or more instances shall be
         construed as a further or continuing waiver of such condition or term
         or of any other condition or term.

10.13    This Agreement shall be binding upon and inure to the benefit of and be
         enforceable by the parties hereto and their respective successors and
         permitted assigns.

<PAGE>

IN WITNESS WHEREOF the respective parties hereto have executed this Agreement by
their duly authorized officers on the date appearing below their signatures.

JOHNS HOPKINS UNIVERSITY                    ZORAX, Inc.

By:                                         By:
   ---------------------------------           --------------------------------
Theodore O. Poehler, Ph.D.                  Uwe Reischl, M.D., Ph.D.
Vice Provost for Research                   President

Date:                                       Date:
     -------------------------------             ------------------------------

I have read and agree to abide by the terms of this Agreement

By:                                         By:
   ---------------------------------           --------------------------------

Dr.:                                        Dr.:
    --------------------------------            -------------------------------

Date:                                       Date:
     -------------------------------             ------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]